scholarly journals Equally Knocking on the Door of Medical Breakthroughs: Safety and Efficacy of a New Anti-Cancer Drug Pamica (PICNH<sub>2</sub>Ca) for Late Stage Cancer Patients

2017 ◽  
Vol 05 (02) ◽  
pp. 49-54
Author(s):  
Haixiang Lin ◽  
Fang Liu
Author(s):  
M. Aldea ◽  
L. Cerbone ◽  
A. Bayle ◽  
C. Parisi ◽  
C. Sarkozy ◽  
...  

2006 ◽  
Vol 31 (1) ◽  
pp. 63-69 ◽  
Author(s):  
Sean Ransom ◽  
William P. Sacco ◽  
Michael A. Weitzner ◽  
Lora M. Azzarello ◽  
Susan C. McMillan

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 232 ◽  
Author(s):  
Martin L. Ashdown ◽  
Andrew P. Robinson ◽  
Steven L. Yatomi-Clarke ◽  
M. Luisa Ashdown ◽  
Andrew Allison ◽  
...  

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are generally low, with few exceptions, regardless of the solid cancer type or drug regimen. We investigated CR rates reported in the literature for clinical trials using chemotherapy alone, across a wide range of tumour types and chemotherapeutic regimens, to determine an overall CR rate for late-stage cancers. A total of 141 reports were located using the PubMed database. A meta-analysis was performed of reported CR from 68 chemotherapy trials (total 2732 patients) using standard agents across late-stage solid cancers—a binomial model with random effects was adopted. Mean CR rates were compared for different cancer types, and for chemotherapeutic agents with different mechanisms of action, using a logistic regression. Our results showed that the CR rates for chemotherapy treatment of late-stage cancer were generally low at 7.4%, regardless of the cancer type or drug regimen used. We found no evidence that CR rates differed between different chemotherapy drug types, but amongst different cancer types small CR differences were evident, although none exceeded a mean CR rate of 11%. This remarkable concordance of CR rates regardless of cancer or therapy type remains currently unexplained, and motivates further investigation.


2019 ◽  
Vol 42 (8) ◽  
pp. 675-681
Author(s):  
Jinhai Huo ◽  
Jiang Bian ◽  
Zhigang Xie ◽  
Young-Rock Hong ◽  
Diana J. Wilkie ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Caroline Lozahic ◽  
Helen Maddock ◽  
Hardip Sandhu

Anti-cancer treatment regimens can lead to both acute- and long-term myocardial injury due to off-target effects. Besides, cancer patients and survivors are severely immunocompromised due to the harsh effect of anti-cancer therapy targeting the bone marrow cells. Cancer patients and survivors can therefore be potentially extremely clinically vulnerable and at risk from infectious diseases. The recent global outbreak of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its infection called coronavirus disease 2019 (COVID-19) has rapidly become a worldwide health emergency, and on March 11, 2020, COVID-19 was declared a global pandemic by the World Health Organization (WHO). A high fatality rate has been reported in COVID-19 patients suffering from underlying cardiovascular diseases. This highlights the critical and crucial aspect of monitoring cancer patients and survivors for potential cardiovascular complications during this unprecedented health crisis involving the progressive worldwide spread of COVID-19. COVID-19 is primarily a respiratory disease; however, COVID-19 has shown cardiac injury symptoms similar to the cardiotoxicity associated with anti-cancer therapy, including arrhythmia, myocardial injury and infarction, and heart failure. Due to the significant prevalence of micro- and macro-emboli and damaged vessels, clinicians worldwide have begun to consider whether COVID-19 may in fact be as much a vascular disease as a respiratory disease. However, the underlying mechanisms and pathways facilitating the COVID-19-induced cardiac injury in cancer and non-cancer patients remain unclear. Investigations into whether COVID-19 cardiac injury and anti-cancer drug-induced cardiac injury in cancer patients and survivors might synergistically increase the cardiovascular complications and comorbidity risk through a “two-hit” model are needed. Identification of cardiac injury mechanisms and pathways associated with COVID-19 development overlapping with anti-cancer therapy could help clinicians to allow a more optimized prognosis and treatment of cancer survivors suffering from COVID-19. The following review will focus on summarizing the harmful cardiovascular risk of COVID-19 in cancer patients and survivors treated with an anti-cancer drug. This review will improve the knowledge of COVID-19 impact in the field of cardio-oncology and potentially improve the outcome of patients.


2020 ◽  
Vol 11 (1) ◽  
Author(s):  
JungHo Kong ◽  
Heetak Lee ◽  
Donghyo Kim ◽  
Seong Kyu Han ◽  
Doyeon Ha ◽  
...  

Abstract Cancer patient classification using predictive biomarkers for anti-cancer drug responses is essential for improving therapeutic outcomes. However, current machine-learning-based predictions of drug response often fail to identify robust translational biomarkers from preclinical models. Here, we present a machine-learning framework to identify robust drug biomarkers by taking advantage of network-based analyses using pharmacogenomic data derived from three-dimensional organoid culture models. The biomarkers identified by our approach accurately predict the drug responses of 114 colorectal cancer patients treated with 5-fluorouracil and 77 bladder cancer patients treated with cisplatin. We further confirm our biomarkers using external transcriptomic datasets of drug-sensitive and -resistant isogenic cancer cell lines. Finally, concordance analysis between the transcriptomic biomarkers and independent somatic mutation-based biomarkers further validate our method. This work presents a method to predict cancer patient drug responses using pharmacogenomic data derived from organoid models by combining the application of gene modules and network-based approaches.


2017 ◽  
Vol 35 (31_suppl) ◽  
pp. 188-188
Author(s):  
Alyson B. Moadel ◽  
Fernando J. Camacho ◽  
Nicolas Schlecht

188 Background: Socioeconomic disparities in psychosocial outcomes among cancer patients have been documented. High interest in peer support and mind-body therapies across diverse populations presents an opportunity for enhancing end-of-life care in the underserved setting. We present the results of a psychosocial needs assessment, and the findings from a feasibility trial in which peer navigators (PN; cancer survivor volunteers) were taught to deliver Loving Kindness (LK) Meditation in preparation for their role as end-of-life “Doulas”. Methods: (1) A survey of psychosocial symptoms and needs was administered to a convenience sample of 56 stage IV patients from an NCI-designated cancer center in Bronx, NY. Patients were female (75%), African American (43%), Hispanic (45%), and 56 M years old. (2) A feasibility trial randomly assigned 9 patients to receive LK meditation delivered by 1 of 4 trained PNs or a professional meditation instructor. The trial was rated on 8 measures of feasibility as set forth by Bowen et al 2009. Results: Patients reported high sadness (66%), anxiety (54%), anger (41%), and spiritual distress (18%) with 70% endorsing an interest in mind-body therapies “such as meditation”, and 46% an interest in a PN. In the LK meditation feasibility trial, patients reported improved positive affect scores by a clinically significant margin of 13%, with equivalent impact and satisfaction for PN relative to professional instructor. Conclusions: Inner city late stage cancer patients endorse high distress, and high interest in peer support and mind-body interventions. Feasibility testing demonstrates that LK meditation is responsive to patient preference and demonstrates preliminary efficaciousness. Findings suggest that Doula-delivered meditation for underserved patients presents a unique resource in the palliative care setting.


2012 ◽  
Vol 65 (10) ◽  
pp. 1350-1356 ◽  
Author(s):  
Helio R.N. Alves ◽  
Luis C. Ishida ◽  
Luis H. Ishida ◽  
Julio M. Besteiro ◽  
Rolf Gemperli ◽  
...  

2009 ◽  
Vol 18 (11) ◽  
pp. 1429-1436 ◽  
Author(s):  
Linda E. Francis ◽  
Julie Worthington ◽  
Georgios Kypriotakis ◽  
Julia H. Rose

Sign in / Sign up

Export Citation Format

Share Document